The Health Protection Agency, on behalf of the CJD Incidents Panel, has provided an assessment of the risk associated with each batch of plasma product; has advised which patients needed to be assessed and, where necessary, subsequently contacted, and has given advice on how the possible risks to public health should be managed.In the light of these assessm...